DFCM
CCCC icon

Dark Forest Capital Management’s C4 Therapeutics CCCC Stock Holding History

Dark Forest Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-134
Closed -$421 – 1074
2023
Q1 		$421 Buy
+134
New +$789 ﹤0.01% 1106
2022
Q3 		– Sell
-303
Closed -$2K – 1163
2022
Q2 		$2K Sell
303
-270
-47% -$2.38K ﹤0.01% 713
2022
Q1 		$13K Buy
+573
New +$13.9K ﹤0.01% 942

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Dark Forest Capital Management's CCCC Position: Q2 2023 in Review

Dark Forest Capital Management sold out of C4 Therapeutics (CCCC) in Q2 2023, closing a stake of 134 shares — an estimated $421 sold.

Dark Forest Capital Management first reported a position in CCCC in Q1 2022 and held it in 3 quarters. The position peaked at $13K in Q1 2022. 100 funds tracked by Wall St. Rank hold CCCC as of Q2 2023.

  • Dark Forest Capital Management reported no remaining C4 Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Dark Forest Capital Management sold 134 C4 Therapeutics shares in Q2 2023, an estimated $421.
  • Dark Forest Capital Management first reported a position in C4 Therapeutics in Q1 2022 and held it in 3 quarters.
  • Dark Forest Capital Management's C4 Therapeutics position peaked at $13K in Q1 2022.
  • 100 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2023.

Based on Dark Forest Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.